PODCAST · health
Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated
by NotebookLM
Nirsevimab effectiveness, number needed to immunize and impact on severeRSV outcomes in preterm, high-risk and healthy-term infants, Quebec,CanadaSara Carazo, MD PhD1,2,3 – Manale Ouakki, MSc3 – Danuta M Skowronski, MD FRCPC4 –Maude Paquette, MD5,6,7 – Nicholas Brousseau, MD MSc FRCPC1,2,3 – Denis Talbot,PhD1,2 – Charles-Antoine Guay, MD MSc1,3 – Caroline Quach, MD MSc5,6 – Rodica Gilca,MD PhD1,2,3 – Jesse Papenburg, MD MSc8,91Social and preventive medicine department, Faculty of medicine, Laval University, Québec,Québec, Canada2Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Québec,Québec, Canada3Biological risk unit. Institut national de santé publique du Québec, Québec, Québec, Canada4Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver,British Columbia, Canada5Department of Microbiology, University of Montreal,
No episodes available yet.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Nirsevimab effectiveness, number needed to immunize and impact on severeRSV outcomes in preterm, high-risk and healthy-term infants, Quebec,CanadaSara Carazo, MD PhD1,2,3 – Manale Ouakki, MSc3 – Danuta M Skowronski, MD FRCPC4 –Maude Paquette, MD5,6,7 – Nicholas Brousseau, MD MSc FRCPC1,2,3 – Denis Talbot,PhD1,2 – Charles-Antoine Guay, MD MSc1,3 – Caroline Quach, MD MSc5,6 – Rodica Gilca,MD PhD1,2,3 – Jesse Papenburg, MD MSc8,91Social and preventive medicine department, Faculty of medicine, Laval University, Québec,Québec, Canada2Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Québec,Québec, Canada3Biological risk unit. Institut national de santé publique du Québec, Québec, Québec, Canada4Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver,British Columbia, Canada5Department of Microbiology, University of Montreal,
HOSTED BY
NotebookLM
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated have?
Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated currently has 0 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated about?
Nirsevimab effectiveness, number needed to immunize and impact on severeRSV outcomes in preterm, high-risk and healthy-term infants, Quebec,CanadaSara Carazo, MD PhD1,2,3 – Manale Ouakki, MSc3 – Danuta M Skowronski, MD FRCPC4 –Maude Paquette, MD5,6,7 – Nicholas Brousseau, MD MSc FRCPC1,2,3 – Denis...
How often does Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated release new episodes?
Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated is no longer actively publishing new episodes, but the existing catalog remains available.
Where can I listen to Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated?
You can listen to Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated?
Nirsevimab's Impact on Infant RSV Outcomes in Quebec: NotebookLM generated is created and hosted by NotebookLM.
URL copied to clipboard!